Only first 10,000 results will be saved in the file.
No item is selected. Use checkboxes to select search results.
Displaying 351-375 of 1083 results.
{{ selectedCountPage }} items selected on this page,{{ selectedCountPage }} item selected on this page,{{ selectedCountTotal }} item in total{{ selectedCountTotal }} items in total
pneumonitis in COVID-19 patients
Design:
A randomized, single-blinded clinical trial with a parallel-group (...)
Participants/Inclusion and exclusion criteria:
Participants: COVID-19 patients with more than 50% lung (...) laser treatment in addition to the current standard of care for COVID-19.
Control group: Patients will
Study aim:
Determining the effect of hemoperfusion on the improvement of symptoms of Covid-19(...) severe symptoms of COVID-19 will undergo hemoperfusion in two sessions . The variables studied in this (...)
Participants/Inclusion and exclusion criteria:
Patients with severe symptoms following Covid-19 with pulmonary
Study aim:
Comparison of clinical symptoms of patients with Covid19 in the studied groups
Comparison of disease severity and status in patients with Covid19 in the study groups
Comparison of clinical improvement and mortality in patients with Covid19 in the study groups
Comparison of oxygen
Study aim:
Study of intra-venous ozonated normal saline on severe cases of COVID-19
Design:
Randomised, superiority, parallel group trial, double blind, outcome assessment.phase 3. block randomization (...) .
Participants/Inclusion and exclusion criteria:
Inclusion criteria are Severe cases of Covid-19 with chest CT
COVID-19 patients' mouths
Design:
Sixty patients are randomly assigned to intervention group 1 (...) diagnosis of COVID-19 infection referred to Farshchian Hospital in Hamadan.
Participants/Inclusion and exclusion criteria:
Clinical diagnosis of COVID-19 infection based on the opinion of the treating physician
with Covid-19
Design:
Parallel single-blind randomized clinical trial study
Settings and conduct (...) blocks randomization are divided into two groups including receiving standard treatment of Covid-19 and (...) national protocol)
Main outcome variables:
Clinical outcome and prognosis of patients with Covid-19
mild to moderate COVID-19
Design:
This is a randomized triple-blind, parallel group clinical trial on 40 patients with mild to moderate hospitalized covid-19 (20 patients in treatment group and 20 (...) laboratory diagnosis of mild to moderate covid-19 who refer to Quem Hospital, Mashhad, Iran. They whether
saturation in patients with COVID-19
Design:
A clinical trial with a control group, with parallel groups (...) :
Confirmation of the COVID-19;
hospitalization of the patient;
more than 25% of pulmonary involvement in chest (...) treatment for COVID-19 as the intervention group (except for not receiving packed cells).
Main outcome
COVID-19
Design:
Randomized non-blinded clinical trial, with a sample size of 72, Phase 3 Clinical (...) received the prescribed medications to treat COVID-19, will be received the cupping therapy on the (...) the prescribed medications for the treatment of COVID-19 according to the protocol of the Ministry of
in treatment-resistant Coronavirus disease 2019 (COVID-19) patients.
• Determining the percentage of (...) cell infusion in patients with resistant COVID-19
Design:
8 patients in the case group and 6 patients (...) with COVID-19 related severe pneumonia (2x10^6 cell /kg) in the intensive care unit (ICU) and infusion
Study aim:
Evaluation of the effect of Arbidol in treatment of covid19
Design:
Clinical trial of Openlabel, Phase 3 in 60 patients. Patients will be divided into two groups without the need for (...) diagnosed with COVID-19 infection based on PCR test for oropharyngeal and nasopharyngeal secretions and/or
Study aim:
Evaluation of slow release mucoadhesive paste of” MUCODENTOL “ in oral vestibule on symptoms of COVID-19 disease in staff of hospitals of LUMS
Design:
Clinical trial with intervention-control groups.
A blind, accidental strain, Phase 1 on 1300 patients.
The rand function of the Excel
-beta after using red light on the skin of COVID-19 patients with pneumonia
Design:
Randomized (...) effect will be compared among the groups with COVID-19 pneumonia. Before and 3 days after using (...) with COVID-19 pneumonia who get photobiomodulation.
Control group: Patients with COVID-19 pneumonia who
Study aim:
Investigating Lavender syrup efficacy to improve cough severity in definite or highly suspected COVID-19 patients
Design:
Clinical trial with control group; with parallel groups; not blinded; randomized; phase 3 on 30 patients. Blocks of size 4 was used for randomization.
Settings and conduct:
The
, cardiac and renal failure in COVID-19 patients
Design:
Clinical trial with control group, with parallel (...) /Inclusion and exclusion criteria:
Inclusion criteria: COVID-19 patients with respiratory, heart or kidney (...) repeated every week.
Control group: Patients receive common treatment for COVID-19 based on national
COVID-19
Design:
a non-randomized open label, parallel group clinical trial on 60 patients With covid(...) :
60 COVID-19 infected patients in Razi Hospital, Ahvaz, at the same time as receiving the national treatment protocol for CoVID-19 treatment, are categorized in two groups receiving nano-curcumin capsules
COVID-19.
Design:
Trial type: Superiority
Study plan: Parallel
Sample size: 70 (intervention group (...) referred with the persistent olfactory dysfunction were diagnosed as confirmed COVID-19 cases by positive RT-PCR or the COVID-19 IgG/IgM Rapid Test Cassette.
Patients with a history of Parkinson's
severe COVID-19
Design:
This study is a single-center, randomized, open-labeled, controlled and parallel (...) .
Participants/Inclusion and exclusion criteria:
Inclusion criteria:
Confirmed diagnosis of COVID-19, with either lung CT-Scan result, which is typical for COVID-19 pulmonary involvement,or RT-PCR confirmation;The
study at hospitalized covid-19 patients. Nasal spray of interferon beta 1a will be prepared by sponsor (...)
Participants/Inclusion and exclusion criteria:
Patients who have Covid-19 based on the CT-scan data or PCR and have no allergic sensitivity to the interferon products or participated in any other trials of Covid-19
& laboratory symptoms of hospitalized COVID-19 patients
Design:
Clinical trial involving a control group with (...) patients
Settings and conduct:
- Place: wards for hospitalized COVID-19 patients
- Method: by blinding (...) : hospitalized definite COVID-19 patients diagnosed via PCR & CT scan of the lungs, patients' filling out a
covid19 pneumonia. Eligible patients enter the study and are divided into two groups after obtaining (...) compared.
Participants/Inclusion and exclusion criteria:
Patients with covid19 have been admitted to (...) groups:
This study examines patients with covid19 who are hospitalized. Patients who are eligible to
simple randomization. Patients in the control group will be prescribed a standard regimen for COVID-19(...) standard regimen for COVID-19. The routine lab data blood cell count, ESR, CRP, CT scan of lungs (...) groups.
Participants/Inclusion and exclusion criteria:
Inclusion Criteria: Laboratory confirmed COVID-19
treatment in patients with covid19
Design:
Clinical trial with control group, with parallel, double blind (...) /Inclusion and exclusion criteria:
Entry:Age 18 to 70 years; Detection of COVID-19 in the last 24 to 48 hours; o2sat <93% or RR> 24 or Pao2 / Fio2 <300; Covid-19 patients hospitalized with hospital indications
Study aim:
Evaluation the effect of berberine in covid-19 patients
Design:
A randomized, blinded, placebo controlled clinical trial with a parallel group design of 40 patients,
randomizing with the table (...) , 40 patients with covid-19 disease were selected and randomly assigned to two groups of 20 individuals
Study aim:
Evaluation of the effect of Viroherb and Fenugreek in clinical and paraclinical outcomes and survival rate of patients with mild to moderate form of COVID-19
Design:
Multicenter, randomized (...) /Inclusion and exclusion criteria:
patients aged 18 years or more with mild to moderate form of COVID-19